Casodex — Competitive Intelligence Brief

Casodex (bicalutamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen Receptor Inhibitor [EPC]. Area: Oncology.

marketed Androgen Receptor Inhibitor [EPC] Androgen receptor Oncology

Target snapshot

Casodex (bicalutamide) — ANI Pharmaceuticals. Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Casodex TARGET	bicalutamide	ANI Pharmaceuticals	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	1995-01-01
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen Receptor Inhibitor [EPC] class)

1. · 1 drug in this class
2. ANI Pharmaceuticals · 1 drug in this class
3. Advanz · 1 drug in this class
4. Astellas Pharma · 1 drug in this class
5. Pfizer Inc. · 1 drug in this class
6. Sun Pharma · 1 drug in this class